Zhangjiang Medicine valley News: Youngene Therapeutics has recently been invited byEASD to participate its fifty-sixthannual conference to present oral reports and discussions on the experimental data of YG1699's preclinical diabeticnephropathy. The meeting will be held online at the end of September 2021.At that time, Youngene CMO Dr. PabloLapuerta and Professor Ji Linong will attend and participate in the discussion.

lt is reported that about 30% to 50% of diabetic patients will develop into diabetic nephropathy. Severe nephropathypatients can only rely on renal dialysis or renal transplantation to maintain their daily life, which is a huge burden forpatients and society.At present, there is no effective medicine for treating diabetic nephropathy in the global

pharmaceutical market.According to the latest research data of Youngene Therapeutics, YG1699 has a strong glucosecontrol effect on monkeys with diabetes mellitus accompanied with moderate and severe nephropathy, and preliminaryresult shows that it can not only prevent renal function from deteriorating, but also reverse the impaired renal function,and has the potential to treatment DKD.

YoungeneTherapeutics Co.Ltd, a Clinical - Phase ll stage pharmaceutical company.Founded in 2016 in China.We haveestablished an innovative and differentiatedpipeline of several programs mainly focusing on metabolic disease. YG1699,oneof the leading product has completed Phase / study in USA. The Phase ll studyhas been initiated in the United

States. Chinese clinicalbridging study has also initiated in China.